Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial

Craig Haifer(University of Sydney), Sudarshan Paramsothy(University of Sydney), Nadeem O. Kaakoush(UNSW Sydney), Aiasha Saikal(UNSW Sydney), Simon Ghaly(St Vincent's Hospital Sydney), Tao Yang(St Vincent's Hospital Sydney), Laurence Don Wai Luu(UNSW Sydney), Thomas J. Borody(Centre For Digestive Diseases), Rupert W. Leong(Concord Repatriation General Hospital)

The Lancet. Gastroenterology & hepatology

December 2, 2021

10.1016/s2468-1253(21)00400-3

Cited by 257

Abstract

Related Papers

Metagenomic biomarker discovery and explanation

Nicola Segata, Jacques Izard, Levi Waldron et al.|Genome biology|2011|16.5k

Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis

Kenneth W. Schroeder, William J. Tremaine, Duane M. Ilstrup|New England Journal of Medicine|1987|3k

Bayesian community-wide culture-independent microbial source tracking

Dan Knights, Justin Kuczynski, Emily S. Charlson et al.|Nature Methods|2011|1.9k

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

Paul Moayyedi, Michael G. Surette, Peter T. Kim et al.|Gastroenterology|2015|1.5k

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial

Sudarshan Paramsothy, Michael A. Kamm, Nadeem O. Kaakoush et al.|The Lancet|2017|1.2k